

Q1 growth driven by India business...

About the stock: Glenmark's business is separated into three entities –

- Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others
- Glenmark Life Sciences for manufacturing and marketing APIs
- Innovation New Company (ICHNOS) to focus on discovery and development of novel, first-in-class treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs

Q1FY22 Results: Glenmark reported strong Q1FY22 results.

- Sales were up 26.4% YoY to ₹ 2964.9 crore
- EBITDA in Q1FY22 was at ₹ 573.6 crore, up 20% YoY with margins at 19.3%
- Consequent adjusted PAT was at ₹ 306 crore (up 35.6% YoY)

What should investors do? Glenmark's share price has de-grown by ~0.7x over the past five years (from ~₹ 856 in July 2016 to ~₹ 607 levels in July 2021).

- We retain our BUY rating on the stock

Target Price and Valuation: We value Glenmark at ₹ 680 based on SOTP valuation

Key triggers for future price performance:

- In India, it is the market leader in dermatology and improving its presence in respiratory, CVS, anti-infectives and anti-diabetics, in particular. It has also forayed into consumer health segment focusing on Rx-OTC switch products (~₹ 150 crore) led by two brands, Candid and Scalpe+
- In the US, traction from the newly commissioned US based Monroe facility will be the key determinant besides sustained product launches
- The management expects margins to improve due to cost rationalisation measures and decline in R&D expenses as percentage of sales

Alternate Stock Idea: Apart from Glenmark, in healthcare coverage we like Ajanta.

- It is mainly into domestic as well as exports formulations with focus on launching maximum number of first time branded generics launches
- BUY with a target price of ₹ 2695

Key Financial Summary

(₹ Crore)	FY19	FY20	FY21	5 year CAGR (FY16-21)	FY22E	FY23E	2 year CAGR (FY21-23E)
Revenues	9865.5	10641.0	10943.9	7.4	12218.5	13111.8	9.5
EBITDA	1585.8	1698.1	2084.4	7.7	2339.4	2689.4	13.6
EBITDA margins (%)	16.1	16.0	19.0		19.1	20.5	
Adjusted PAT	757.8	743.1	925.5	5.5	1003.6	1350.1	20.8
EPS (₹)	26.9	26.4	32.9		35.6	47.9	
PE (x)	17.5	20.9	16.7		11.1	12.0	
EV to EBITDA (x)	12.1	11.8	9.5		8.1	6.7	
RoNW (%)	13.5	12.2	13.1		11.9	13.8	
RoCE (%)	15.3	12.7	13.7		15.9	17.0	

Source: Company, ICICI Direct Research

BUY
Glenmark
A new way for a new world


Particulars

Particular	Amount
Market Capitalisation	₹ 16236 crore
Debt (FY21)	₹ 4785 crore
Cash & equivalent (FY21)	₹ 1139 crore
EV	₹ 19882 crore
52 week H/L (₹)	691/442
Equity capital	₹ 28.2 crore
Face value	₹ 1

Shareholding pattern

	(in %)	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21
Promoter	46.6	46.6	46.6	46.6	46.6	46.6
Others	53.4	53.4	53.4	53.4	53.4	53.4

Price Chart



Recent Event & Key risks

- Received CGT exclusivity in US for Theophylline 450mg
- **Key Risk:** (i) Continued price erosion in Derma US portfolio (ii) Delay in unlocking of innovation business

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com
Mitesh Shah
mitesh.shah@icicisecurities.com

Key takeaways of recent quarter & conference call highlights

Q1FY22 Results: Robust performance

- Q1 revenues grew 26.4% YoY to ₹ 2964.9 crore. Domestic sales grew 57.1% YoY to ₹ 1225 crore due to growth in both Covid and non Covid portfolio. US sales grew 6.1% to ₹ 787.8 crore, led by new launches. Europe business grew 11.7% YoY to ₹ 305.9 crore amid Covid restrictions in some countries partially being offset by growth in key markets. RoW markets grew 26.7% YoY to ₹ 268.6 crore whereas API segment grew 29.5% YoY to ₹ 304 crore. LatAm market grew 2.6% YoY to ₹ 67.5 crore due to a challenging environment in Brazil. EBITDA margins declined 104 bps YoY to 19.3% mainly due to lower gross margins. EBITDA grew 20% YoY to ₹ 573.6 crore. Adjusted PAT grew 35.6% YoY to ₹ 306.5 crore
- The company has received CGT exclusivity for Theophylline extended release tablets USP,450 mg and has a portfolio of 172 ANDAs while another 44 are pending approval, of which 21 are Para IV applications. However, Glenmark's derma portfolio is facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides sustained product launches

Q1FY22 Earnings Conference Call highlights

India

- A ₹ 350 crore Favipiravir in Q1FY22, Ex this, India business grew 12.2% led mainly by volume growth
- Almost nil sales of Favipiravir in July
- Glenmark is ranked first in antivirals, second in dermatology market, fourth in respiratory and sixth in the cardiology market in India
- Launched seven new products in Q1FY22
- Two to three big launches expected in this month and next month
- Secondary sales of Glenmark's Consumer Care business grew 24% YoY during the quarter
- Candid Powder recorded its highest ever secondary sales in June 2021
- Similarly, LaShield and Scalpe Plus both recorded their highest secondary sales in the quarter
- The company also launched Candid Cream during the quarter, which is available in more than 30,000 outlets currently
- Nasal spray for Covid-19 - Glenmark has recently signed an exclusive long term agreement with Canadian biotech SaNOtize to commercialise Nitric Oxide Nasal spray for Covid-19 treatment in Indian and other Asian markets
- Studies show that Nitric Oxide nasal spray is safe and highly effective in reducing viral load in Covid-19 patients and reduces onward transmission
- Phase III clinical trial is expected to be completed, followed by commercial launch under the brand name FabiSpray in India in Q3FY22
- Expects continue to grow better than industry
- Q2 expects negative growth amid higher base of Faviflu

US

- The company filed eight ANDAs, including three filings from Monroe.
- Expects to file 18-20 ANDAs in FY22 including four to five filings from Monroe
- Cumulative approvals were at 172 and 44 pending approvals of which 21 are para IV filings

- Expects 10-12 approvals annually
- US business expected to grow 10% in FY22
- No single products have more than US\$ 15 million sales

Russian and CIS

- In Russia and CIS secondary sales grew 42% YoY in Q1FY22
- In Russia, as per Q1 IQVIA, Glenmark's revenues grew 29% in value terms vis-à-vis 13.2% growth in the overall retail market.
- In Q1FY22, the company commercialized Ryaltris in Russia. Currently, it is focusing on building the distribution of the product across the region

RoW

- In the Asia region, a strong second wave of Covid especially in South East Asian countries impacted marketing activities
- Despite these challenges, secondary sales of the company grew 20% YoY during the quarter in the region, with strong growth in key markets like Philippines and Sri Lanka
- The company also witnessed a recovery in the Middle East/Africa region with secondary sales growth of 52% YoY with growth witnessed in markets like Kenya, South Africa and Saudi Arabia
- Covid products are negligible in RoW revenues

Europe

- The company witnessed a mixed performance in Western Europe
- While growth was affected by continued Covid restrictions in some countries, key markets like UK and Netherlands witnessed positive growth, The Central Eastern European region witnessed healthy growth across most key markets
- Among the key launches, the company launched one product each in UK, Germany and Spain during the quarter, respectively
- Glenmark became one of the first generic companies to successfully launch Tiotropium Dry Powder Inhaler, the bioequivalent version of Spiriva Handihaler under the brand name of Tiogiva in the UK in Q1FY22
- The company has a strategic exclusive in-licensing agreement to market Tiotropium DPI in Western Europe
- The company is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva in Ireland, Sweden, Finland and Norway; Tavulus in Denmark, Spain and Netherlands; and Tiotropium Glenmark in Germany.

Latin America

- Revenue growth was impacted by Brazil where the market remained challenging due to the pandemic
- However, it witnessed a recovery in this region with most other markets recording positive growth momentum during the quarter including Mexico which grew 63% YoY during the quarter

Glenmark Life Sciences (API)

- Revenues including captive consumption grew 32.2% YoY to ₹ 524.9 crore
- Margins were at 31.3%

Others

- R&D was ₹ 284 crore in Q1FY22, 9.57%

- US\$ 22 million spend in ICHNOS in Q1FY22
- Expects 10.5% in FY22
- Capex guidance -- 650-700 crore in FY22 and 650 crore in FY23

Key Guidance/objective for FY22

- Revenue growth of 10-15% during the year
- Sustain EBITDA margin performance at similar levels of FY21
- Reduce debt by at least ₹ 1600 crore through a combination of free cash generation and IPO proceeds during the year
- Also, ₹ 1200 crore from IPO proceed
- Total ₹ 400 crore from internal accruals
- Post FY22, strategic priority to enhance free cash generation for further debt reduction; prioritizing over R&D investments and capital expenditure
- Close one or two out-licensing agreements at Ichnos
- Other expenditure expects more than 26%, mostly other expenditure in H2 is higher than H1
- Expect strong FY22



Exhibit 1: Variance Analysis

	Q1FY22	Q1FY21	Q4FY21	YoY (%)	QoQ (%)	Comments
Revenue	2,964.9	2,344.8	2,859.9	26.4	3.7	YoY growth driven by 57% growth in domestic formulations mainly led by surge in Favipiravir sales in second wave
Raw Material Expenses	1,139.0	808.4	938.4	40.9	21.4	
Gross Margin (%)	61.6	65.5	67.2	-394 bps	-560 bps	YoY impacted amid product mix led to Favipiravir
Employee Expenses	596.4	509.6	537.2	17.0	11.0	
Other Expenditure	655.9	548.7	860.9	19.5	-23.8	
EBITDA	573.6	478.1	523.4	20.0	9.6	
EBITDA (%)	19.3	20.4	18.3	-104 bps	104 bps	YoY decline in gross margins partially offset by lower other expenditure and staff cost
Interest	75.6	93.7	83.3	-19.3	-9.3	
Depreciation	113.1	113.2	111.1	-0.1	1.8	
Other Income	58.6	58.5	8.5	0.2	590.6	
PBT before EO & Forex	443.6	329.6	337.5	34.6	31.4	
Less: EO & Forex	0.0	-28.0	0.0	NA	NA	
PBT	443.6	357.6	337.5	24.0	31.4	
Tax	137.0	103.6	103.6	32.3	32.2	
PAT before MI	306.5	254.0	233.9	20.7	31.1	
Adj. Net Profit	306.5	226.1	233.9	35.6	31.1	Delta vis-à-vis EBITDA mainly due to lower interest and depreciation
Key Metrics						
US	787.8	742.6	801.2	6.1	-1.7	Growth primarily driven by new product launches
Europe	305.9	273.9	422.3	11.7	-27.6	YoY growth driven by positive growth in key markets like UK, Netherlands and strong growth in Central Eastern European region
India	1,225.0	779.9	823.8	57.1	48.7	Favipiravir reported ₹ 350 crore in Q1FY22, ex this India business grew 12.2%
Latin America	67.5	65.8	129.9	2.6	-48.0	Revenue growth impacted by Brazil where the market remained challenging due to the pandemic
RoW markets	268.6	212.0	334.2	26.7	-19.6	Russia and CIS markets secondary sales having grown 42% YoY in the region. Asia region secondary sales of the company grew 20% YoY
API	304.0	234.8	331.1	29.5	-8.2	

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

₹ Crore	FY22E			FY23E			Comments
	Old	New	% Change	Old	New	% Change	
Revenue	12,158.7	12,218.5	0.5	13,249.5	13,111.8	-1.0	
EBITDA	2,424.8	2,339.4	-3.5	2,709.4	2,689.4	-0.7	
EBITDA Margin (%)	19.9	19.1	-80 bps	20.4	20.5	6 bps	Reduced as per guidance
PAT	1,185.1	1,457.2	23.0	1,410.4	1,350.1	-4.3	Included proceeds from Glenmark Lifescience IPO
EPS (₹)	42.1	51.7	23.0	50.1	47.9	-4.3	

Source: ICICI Direct Research

Exhibit 3: Assumptions

₹ crore	Current			Earlier			Comments
	FY20	FY21	FY22E	FY23E	FY22E	FY23E	
US	3,140.4	3,076.4	3,354.3	3,627.0	3,383.0	3,653.6	
Europe	1,248.4	1,327.6	1,517.7	1,745.4	1,526.8	1,755.8	
India	3,202.2	3,536.5	4,133.8	4,279.8	3,922.6	4,271.7	
Latin America	535.6	422.6	447.1	469.4	458.5	481.5	
RoW markets	1,285.4	1,262.8	1,424.5	1,567.0	1,420.9	1,563.0	
API	1,023.9	1,207.3	1,276.5	1,340.3	1,326.4	1,392.7	

Source: ICICI Direct Research

Exhibit 4: Financial Summary

	Revenues (₹ crore)	Growth (%)	Adj. EPS (₹)	Growth (%)	P/E (x)	EV/EBITDA (X)	RoNW (%)	RoCE (%)
FY20	10641	7.9	26.4	-1.9	20.9	11.8	12.2	12.7
FY21	10944	2.8	32.9	24.6	16.7	9.5	13.1	13.7
FY22E	12219	11.6	35.6	8.4	11.1	8.1	11.9	15.9
FY23E	13112	7.3	47.9	34.5	12.0	6.7	13.8	17.0

Source: ICICI Direct Research

Exhibit 5: Revenue Breakup

	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	CAGR (FY16-21) %	CAGR (FY21-23E) %
US	2420	3701	3208	3139	3140	3076	3354	3627	CAGR 4.9%	CAGR 8.6%
India	2102	2304	2514	2777	3202	3537	4134	4280	CAGR 11.0%	CAGR 10.0%
Europe	717	710	906	1121	1248	1328	1518	1745	CAGR 13.1%	CAGR 14.7%
Latin America	750	518	407	418	536	423	447	469	-CAGR 10.8%	CAGR 5.4%
RoW markets	903	989	1099	1276	1285	1263	1425	1567	CAGR 6.9%	CAGR 11.4%
API	668	809	878	949	1024	1207	1277	1340	CAGR 12.6%	CAGR 5.4%
Total Revenues	7650	9186	9103	9865	10641	10944	12219	13112	CAGR 7.4%	CAGR 9.5%

Source: ICICI Direct Research

Exhibit 6: Trends in Quarterly Performance

(₹ Crore)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	YoY (%)	QoQ (%)
Total Operating Income	2165.6	2581.3	2555.0	2563.5	2322.9	2815.0	2735.6	2767.5	2344.8	2952.5	2786.8	2859.9	2964.9	26.4	3.7
Raw Material Expenses	758.8	880.8	862.0	860.7	810.1	986.1	926.3	976.1	808.4	1040.7	911.4	938.4	1139.0	40.9	21.4
% of revenue	35.0	34.1	33.7	33.6	34.9	35.0	33.9	35.3	34.5	35.2	32.7	32.8	38.4		
Gross Profit	1406.8	1700.5	1693.0	1702.8	1512.8	1828.9	1809.2	1791.4	1536.4	1911.8	1875.4	1921.5	1825.9	18.8	-5.0
Gross Profit Margin (%)	65.0	65.9	66.3	66.4	65.1	65.0	66.1	64.7	65.5	64.8	67.3	67.2	61.6	-394 bps	-560 bps
Employee Expenses	452.5	605.9	503.1	494.6	486.7	686.6	557.2	524.2	509.6	700.3	596.6	537.2	596.4	17.0	11.0
% of revenue	20.9	23.5	19.7	19.3	21.0	24.4	20.4	18.9	21.7	23.7	21.4	18.8	20.1		
Other Manufacturing Expe	607.4	654.5	755.3	844.0	684.2	691.9	811.9	801.5	548.7	658.7	748.7	860.9	655.9	19.5	-23.8
% of revenue	28.0	25.4	29.6	32.9	29.5	24.6	29.7	29.0	23.4	22.3	26.9	30.1	22.1		
Total Expenditure	1818.7	2141.2	2120.4	2199.3	1981.0	2364.6	2295.5	2301.8	1866.7	2399.7	2256.7	2336.5	2391.3	28.1	2.3
% of revenue	84.0	83.0	83.0	85.8	85.3	84.0	83.9	83.2	79.6	81.3	81.0	81.7	80.7		
EBITDA	346.9	440.1	434.7	364.1	341.9	450.4	440.1	465.7	478.1	552.8	530.1	523.4	573.6	20.0	9.6
EBITDA Margins (%)	16.0	17.0	17.0	14.2	14.7	16.0	16.1	16.8	20.4	18.7	19.0	18.3	19.3	-104 bps	104 bps
Depreciation	79.4	82.5	83.1	81.0	90.7	94.2	106.0	126.3	113.2	104.1	115.2	111.1	113.1	-0.1	1.8
Interest	79.0	85.1	88.5	81.9	93.0	89.8	96.1	98.5	93.7	80.6	95.4	83.3	75.6	-19.3	-9.3
Other Income	138.2	139.9	-109.0	39.1	1.7	80.8	33.0	44.1	58.5	-31.9	15.1	8.5	58.6	0.2	590.6
Forex & EO	0.0	167.2	0.0	0.0	0.0	0.0	0.0	32.9	28.0	3.1	13.4	0.0	0.0		
PBT	326.7	579.6	154.0	240.3	159.8	347.3	271.0	318.0	357.6	339.4	348.0	337.5	443.6	24.0	31.4
Total Tax	93.7	165.6	37.7	78.6	50.6	91.8	80.1	97.7	103.6	105.4	99.8	103.6	137.0	32.3	32.2
Tax rate (%)	28.7	28.6	24.5	32.7	31.6	26.4	29.6	30.7	29.0	31.1	28.7	30.7	30.9	193 bps	18 bps
PAT	233.0	414.0	116.3	161.7	109.3	255.5	190.8	220.3	254.0	234.0	248.2	233.9	306.5	20.7	31.1
Adjusted PAT	233.0	246.8	116.3	161.7	109.3	255.5	190.8	187.4	226.1	230.9	234.8	233.9	306.5	35.6	31.1
EPS (₹)	8.3	8.8	4.1	5.7	3.9	9.1	6.8	6.7	8.0	8.2	8.3	8.3	10.9		

Source: ICICI Direct Research




Exhibit 7: Valuation

Particulars	FY23E EPS	Multiple (x)	Per share (₹)
Glenmark (ex API)	34.8	10.0	347.9
API			
Targeted Market Cap			9,079
Glenmark's Holding			82.8%
Holding Company Discount			40.0%
API valuation			4512
Per share valuation			332
SOTP valuation			680


Source: ICICI Direct Research, Bloomberg

Exhibit 8: Revenues to grow at CAGR of 10% over FY21-23E




Source: ICICI Direct Research, Company

Exhibit 10: India to grow at CAGR of ~10% over FY21-23E




Source: ICICI Direct Research, Company

Exhibit 12: EBITDA & EBITDA margins trend




Source: ICICI Direct Research, Company

Exhibit 14: PAT & PAT margins trend




Source: ICICI Direct Research, Company

Exhibit 9: US to grow at CAGR of 9% over FY21-23E




Source: ICICI Direct Research, Company

Exhibit 11: Europe to grow at CAGR of 15% over FY21-23E




Source: ICICI Direct Research, Company

Exhibit 13: R&D and R&D as percentage of sales



Source: ICICI Direct Research, Company

Exhibit 15: RoE & RoCE trend



Source: ICICI Direct Research, Company



Exhibit 16: ICICI Direct Coverage Universe (Healthcare)

Company	I-Direct	CMP	TP	Rating	M Cap	EPS (₹)					PE(x)				RoCE (%)				RoE (%)			
	Code	(₹)	(₹)		(₹ cr)	FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E	
Ajanta Pharma	AJAPHA	2234	2,695	Buy	19332	53.4	74.0	80.8	89.8	41.9	30.2	27.6	24.9	24.7	29.0	24.9	24.0	18.1	21.8	20.2	19.2	
Alembic Pharma	ALEMPHA	770	885	Hold	15140	44.4	59.9	35.2	44.3	17.3	12.9	21.9	17.4	21.0	24.2	12.7	14.8	27.1	23.0	12.3	13.8	
Apollo Hospitals	APOHOS	4304	4,510	Hold	61886	22.6	7.9	60.4	76.8	190.6	547.6	71.3	56.0	10.2	6.3	15.5	18.2	9.7	2.5	15.8	17.2	
Aurobindo Pharma	AURPHA	741	865	Hold	43424	48.8	55.0	54.2	61.8	15.2	13.5	13.7	12.0	17.2	16.8	14.4	15.1	17.0	14.7	12.7	12.8	
Biocron	BIOCON	367	400	Hold	43986	5.8	6.1	6.1	12.5	63.0	60.2	59.9	29.2	10.2	7.6	8.7	12.5	10.4	9.6	8.9	15.6	
Cadila Healthcare	CADHEA	532	583	Hold	54463	14.0	21.5	20.8	22.0	38.1	24.8	25.5	24.2	10.7	12.6	13.1	12.9	13.8	16.9	12.6	12.1	
Cipla	CIPLA	890	1,205	Buy	71783	19.2	29.9	35.5	41.6	46.3	29.8	25.1	21.4	12.0	16.3	17.9	18.4	9.8	13.1	14.0	14.5	
Divi's Lab	DIVLAB	4900	5,815	Buy	130081	51.9	74.7	94.7	116.3	94.5	65.6	51.8	42.1	23.9	27.6	28.8	29.2	18.8	21.3	22.5	23.0	
Dr Reddy's Labs	DRREDD	4672	5,250	Hold	77727	121.8	117.3	126.8	197.3	38.4	39.8	36.8	23.7	9.6	13.1	12.9	16.5	13.0	11.1	10.8	14.7	
Glenmark Pharma	GLEPHA	575	680	Buy	16225	26.4	32.9	35.6	47.9	21.8	17.5	16.1	12.0	12.7	13.7	15.9	17.0	12.2	13.1	11.9	13.8	
Hikal	HIKCHE	676	590	Hold	8339	8.1	10.8	16.5	19.6	83.5	62.6	41.0	34.4	12.8	15.1	17.2	18.4	12.2	14.3	18.1	17.9	
Ipca Laboratories	IPCLAB	2408	2,560	Buy	30552	47.6	89.9	88.2	102.4	50.6	26.8	27.3	23.5	17.6	27.1	22.2	21.5	16.6	24.2	19.3	18.4	
Jubilant Pharmova	JUBLIF	632	850	Buy	10067	44.6	37.4	59.9	84.9	14.2	16.9	10.6	7.4	11.7	13.7	18.2	22.4	12.7	12.6	16.9	19.5	
Lupin	LUPIN	969	1,025	Hold	43983	-12.7	26.9	40.0	44.6	NA	36.1	24.2	21.7	9.7	9.0	12.6	13.2	-4.6	8.8	11.8	11.9	
Narayana Hrudayalaya	NARHRU	500	620	Buy	10222	6.4	-0.7	12.3	15.6	78.8	NA	40.6	32.1	11.0	1.2	14.5	16.8	11.4	-1.3	18.6	19.3	
Natco Pharma	NATPHA	994	1,040	Hold	18130	25.3	24.2	19.4	22.6	39.3	41.1	51.3	44.0	14.0	13.1	9.7	10.9	12.2	10.7	8.1	8.8	
Sun Pharma	SUNPHA	780	800	Hold	187208	16.8	30.0	25.1	28.6	46.5	26.0	31.0	27.3	10.0	14.4	15.1	15.3	8.9	15.5	12.0	12.2	
Syngene Int.	SYNINT	627	780	Buy	25086	10.3	10.1	11.0	15.6	60.9	62.0	56.9	40.3	14.5	11.5	13.1	16.6	16.8	13.5	13.6	16.1	
Torrent Pharma	TORPHA	2925	3,250	Buy	49503	60.6	74.0	78.5	101.5	48.3	39.5	37.2	28.8	15.4	17.7	20.8	22.2	21.2	21.4	19.4	21.1	
Shalby	SHALIM	190	210	Hold	2229	2.6	3.9	4.8	5.3	74.3	48.4	39.3	35.5	7.2	6.5	8.3	8.2	3.5	5.1	6.0	6.3	
Aster DM	ASTDM	164	200	Buy	8217	5.7	3.0	10.8	15.0	28.8	55.5	15.2	10.9	7.2	5.4	9.2	11.1	8.7	4.4	13.8	16.1	
Indoco Remedies	INDREM	476	575	Buy	3945	2.6	10.1	16.7	23.9	182.0	47.1	28.4	19.9	4.6	11.8	19.4	21.8	3.5	12.1	17.1	20.2	
Caplin Point	CAPPOI	823	1,135	Buy	6756	28.4	32.0	40.8	47.4	29.0	25.7	20.2	17.4	26.5	25.4	26.1	25.6	22.7	20.4	21.1	20.0	
Granules India	GRANUL	353	430	Buy	9741	12.4	22.2	23.6	28.7	28.4	15.9	15.0	12.3	15.2	24.0	23.4	24.2	16.7	25.3	21.5	21.0	
Laurus Labs	LAULAB	700	785	Buy	34493	4.8	18.3	22.6	28.0	147.1	38.2	31.0	25.0	13.0	31.7	30.6	30.6	14.4	37.9	32.9	29.8	

Source: ICICI Direct Research

Financial Summary

Exhibit 17: Profit and loss statement

(Year-end March)	FY20	FY21	FY22E	₹ crore FY23E
Revenues	10,641.0	10,943.9	12,218.5	13,111.8
Growth (%)	7.9	2.8	11.6	7.3
Raw Material Expenses	3,698.6	3,698.8	4,209.3	4,348.9
Employee Expenses	2,254.8	2,343.7	2,541.9	2,729.9
Other Manufacturing Expenses	2,989.5	2,817.0	3,128.0	3,343.5
Total Operating Expenditure	8,942.9	8,859.6	9,879.2	10,422.4
EBITDA	1,698.1	2,084.4	2,339.4	2,689.4
Growth (%)	7.1	22.7	12.2	15.0
Interest	377.3	353.1	242.8	208.8
Depreciation	417.2	443.6	480.5	522.8
Other Income	159.6	50.2	72.5	65.6
PBT before Exceptional Items	1,063.2	1,337.9	1,688.6	2,023.4
PBT	1,096.1	1,382.5	2,142.2	2,023.4
Total Tax	320.1	412.4	629.6	596.9
PAT before MI	776.0	970.1	1,457.2	1,350.1
PAT	776.0	970.1	1,457.2	1,350.1
Adjusted PAT	743.1	925.5	1,003.6	1,350.1
Growth (%)	-1.9	24.6	8.4	34.5
EPS (Adjusted)	26.4	32.9	35.6	47.9

Source: Company, ICICI Direct Research

Exhibit 18: Cash flow statement

(Year-end March)	FY20	FY21	FY22E	₹ crore FY23E
Profit/(Loss) after taxation	629.1	872.2	1,457.2	1,350.1
Add: Depreciation & Amortization	417.2	443.6	480.5	522.8
Net Increase in Current Assets	-25.7	-546.3	-768.6	-144.2
Net Increase in Current Liabilities	152.7	160.5	329.9	205.7
Others	219.1	201.3	334.6	334.6
CF from operating activities	1,392.4	1,131.2	1,833.5	2,269.0
(Inc)/dec in Fixed Assets	-775.3	-675.3	-650.0	-650.0
(Inc)/dec in Investments	5.0	0.0	0.0	0.0
Others	-3.9	13.8	-5.8	-61.7
CF from investing activities	-774.3	-661.5	-655.8	-711.7
Inc / (Dec) in Equity Capital	0.0	0.0	0.0	0.0
Inc / (Dec) in Loan Funds	7.5	-77.7	-1,600.4	-400.0
Other	-452.2	-364.1	-390.9	-390.9
CF from financing activities	-444.7	-441.8	-1,991.3	-791
Net Cash flow	173.5	27.9	-813.6	766.4
Opening Cash	937.8	1,111.2	1,139.2	325.6
Closing Cash	1,111.2	1,139.2	325.6	1,092.0
Free Cash Flow	617.1	455.9	1,183.5	1,619.0

Source: Company, ICICI Direct Research

Exhibit 19: Balance Sheet

(Year-end March)	FY20	FY21	FY22E	₹ crore FY23E
Equity Capital	28.2	28.2	28.2	28.2
Reserve and Surplus	6,042.3	7,036.4	8,437.3	9,731.1
Total Shareholders fund	6,070.5	7,064.6	8,465.5	9,759.3
Total Debt	4,868.6	4,784.9	3,184.5	2,784.5
Deferred Tax Liability	16.4	28.7	31.6	34.8
Minority Interest	-0.4	-0.4	55.4	58.2
Other Non Current Liabilities	429.3	420.9	442.0	464.1
Source of Funds	11,384.5	12,298.8	12,178.9	13,100.8
Gross Block - Fixed Assets	8,216.9	8,755.7	9,605.7	10,455.7
Accumulated Depreciation	3,241.3	3,684.8	4,165.3	4,688.1
Net Block	6,197.5	6,452.5	6,622.0	6,749.2
Goodwill on Consolidation	52.9	58.0	58.0	58.0
Investments	24.6	24.6	24.6	24.6
Inventory	2,135.6	2,276.8	2,558.2	2,676.2
Cash	1,111.2	1,139.2	325.6	1,092.0
Debtors	2,409.0	2,572.1	2,889.9	3,018.7
Other Current Assets	1,147.8	1,371.5	1,541.0	1,438.3
Total Current Assets	6,803.6	7,359.6	7,314.6	8,225.2
Creditors	2,125.8	2,237.8	2,514.3	2,663.9
Provisions & Other CL	1,174.5	1,067.2	1,120.6	1,176.6
Total Current Liabilities	3,300.3	3,305.0	3,634.8	3,840.5
Net Current Assets	3,503.3	4,054.6	3,679.8	4,384.7
LT L & A, Other Assets	150.5	174.4	183.1	192.3
Deferred Tax Assets	1,455.7	1,534.7	1,611.4	1,692.0
Application of Funds	11,384.5	12,298.8	12,178.9	13,100.8

Source: Company, ICICI Direct Research

Exhibit 20: Key ratios

(Year-end March)	FY20	FY21	FY22E	FY23E
Per share data (₹)				
Adj EPS	26.4	32.9	35.6	47.9
BV	215.6	250.9	300.6	346.6
DPS	2.9	2.5	2.0	2.0
Cash Per Share	115.1	130.9	147.9	166.5
Operating Ratios (%)				
Gross Margin	65.2	66.2	65.6	66.8
EBITDA margins	16.0	19.0	19.1	20.5
Net Profit margins	7.0	8.5	8.2	10.3
Inventory days	73	76	76	74
Debtor days	83	86	86	84
Creditor days	73	75	75	74
Asset Turnover	1.3	1.2	1.3	1.3
EBITDA conversion Rate	82.0	54.3	78.4	84.4
Return Ratios (%)				
RoE	12.2	13.1	11.9	13.8
RoCE	12.7	13.7	15.9	17.0
RoIC	14.2	16.8	17.4	19.6
Valuation Ratios (x)				
P/E	20.9	16.7	11.1	12.0
EV / EBITDA	11.8	9.5	8.1	6.7
Market Cap / Sales	1.5	1.5	1.3	1.2
Price to Book Value	2.7	2.3	1.9	1.7
Solvency Ratios				
Debt / Equity	0.8	0.7	0.4	0.3
Debt / EBITDA	2.9	2.3	1.4	1.0
Current Ratio	1.7	1.9	1.9	1.9

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Mitesh Shah, (cleared all 3 levels of CFA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc. as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.